Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, October 3, 2023
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
[ Tue, Oct 03rd 2023
] - WOPRAI
Gavin Clark-Gartner Initiated (ACRS) at Buy and Held Target at $22 on, Oct 3rd, 2023
Gavin Clark-Gartner of Evercore ISI Group, Initiated "Aclaris Therapeutics, Inc." (ACRS) at Buy and Held Target at $22 on, Oct 3rd, 2023.
Gavin has made no other calls on ACRS in the last 4 months.
There are 3 other peers that have a rating on ACRS. Out of the 3 peers that are also analyzing ACRS, 0 agree with Gavin's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Gavin
- Louise Chen of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $38 on, Tuesday, September 19th, 2023
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $43 on, Tuesday, September 19th, 2023
- Alex Thompson of "Stifel" Maintained at Strong Buy with Increased Target to $20 on, Thursday, September 14th, 2023
